Organization
Genfleet Therapeutics
1 clinical trial
Clinical trial
A Phase I/IIa, Open-Label Dose Escalation and Dose Expansion Study of Intravenous GFH009 Single Agent and in Combination With Venetoclax and Azacitidine in Patients With Relapsed/Refractory Hematologic MalignanciesStatus: Recruiting, Estimated PCD: 2024-06-30